Jim Clement, Executive Director, Cost of Care and Supply Chain Strategy, Aetna Pharmacy Management, Aetna
Mike Ryan, Senior Vice President, U.S. Value, Access and Policy, Bristol-Myers Squibb
Moderator: Tom Knox, President, Fathom Healthcare Solutions
Though still in their infancy in the U.S. health care system, value-based risk sharing agreements are growing in popularity. Market forces have been driving stakeholders to explore new types of financing and access, shifting risk towards value, indications, and/or outcomes-based arrangements. These varying types of value-based arrangements have different goals and metrics for success. Some might allow a payer to minimize risk or manage risk differently; others allow manufactures to create product differentiation and to potentially obtain the full value of the product; while others still might allow for population versus patient management and improved data repositories and informatics systems. Success depends on good contract design, availability of data, and administration.
During this session the panel will discuss the pros and cons of value-based contracts from their varying perspectives. Some of the questions they will address include what’s driving the demand for these types of contracts, how are players looking at specialty versus non-specialty therapies as candidates for these arrangements, what are some of the barriers to doing value-based contracts in the current U.S. landscape, what are the manufacturer versus payer expectations of one another in engaging in these agreements, and finally, how do they see these arrangements evolving over time and with greater adoption.